139 related articles for article (PubMed ID: 37263827)
1. Route of Administration for UGN-101 and Impact on Oncological and Safety Outcomes.
Linehan J; Gottlieb J; Woldu SL; Labbate C; Rose K; Sexton W; Kaimakliotis H; Jacob J; Dickstein R; Nieder A; Bjurlin M; Humphreys M; Ghodoussipor S; Quek M; O'Donnell M; Eisner BH; Feldman AS; Matin SF; Lotan Y; Murray KS
Eur Urol Focus; 2023 Nov; 9(6):1052-1058. PubMed ID: 37263827
[TBL] [Abstract][Full Text] [Related]
2. Antegrade Instillation of UGN-101 (Mitomycin for Pyelocalyceal Solution) for Low-Grade Upper Tract Urothelial Carcinoma: Initial Clinical Experience.
Rosen GH; Nallani A; Muzzey C; Murray KS
J Urol; 2022 Jun; 207(6):1302-1311. PubMed ID: 35130080
[TBL] [Abstract][Full Text] [Related]
3. Mitomycin Gel (UGN-101) as a Kidney-sparing Treatment for Upper Tract Urothelial Carcinoma in Patients with Imperative Indications and High-grade Disease.
Rose KM; Murray KS; Labbate C; Woldu S; Linehan J; Jacob J; Kaimakliotis H; Dickstein R; Feldman A; Matin SF; Lotan Y; Humphreys MR; Sexton WJ
Eur Urol Focus; 2023 Sep; 9(5):807-812. PubMed ID: 37059620
[TBL] [Abstract][Full Text] [Related]
4. Early experience with UGN-101 for the treatment of upper tract urothelial cancer - A multicenter evaluation of practice patterns and outcomes.
Woldu SL; Labbate C; Murray KS; Rose K; Sexton W; Tachibana I; Kaimakliotis H; Jacob J; Dickstein R; Linehan J; Nieder A; Bjurlin MA; Humphreys M; Ghodoussipour S; Quek ML; O'Donnell M; Eisner BH; Feldman AS; Matin SF; Lotan Y
Urol Oncol; 2023 Mar; 41(3):147.e15-147.e21. PubMed ID: 36424224
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Mitomycin Gel (UGN-101) as an Adjuvant Therapy After Complete Endoscopic Management of Upper Tract Urothelial Carcinoma.
Labbate C; Woldu S; Murray K; Rose K; Sexton W; Tachibana I; Kaimakliotis H; Jacob J; Dickstein R; Linehan J; Nieder A; Bjurlin M; Humphreys M; Ghodoussipour S; Quek M; O'Donnell M; Eisner B; Feldman A; Lotan Y; Matin SF
J Urol; 2023 May; 209(5):872-881. PubMed ID: 36657029
[TBL] [Abstract][Full Text] [Related]
6. First analysis of the safety and efficacy of UGN-101 in the treatment of ureteral tumors.
Jacob JM; Woldu SL; Linehan J; Labbate C; Rose KM; Sexton WJ; Tachibana I; Kaimakliotis H; Nieder A; Bjurlin MA; Humphreys M; Ghodoussipour SB; Quek ML; Johnson B; O'Donnell M; Eisner BH; Feldman AS; Murray KS; Matin SF; Lotan Y; Dickstein RJ
Urol Oncol; 2024 Jan; 42(1):20.e17-20.e23. PubMed ID: 37517898
[TBL] [Abstract][Full Text] [Related]
7. The ablative effect of mitomycin reverse thermal gel: Expanding the role for nephron preservation therapy in low grade upper tract urothelial carcinoma.
Kaimakliotis HZ; Tachibana I; Woldu S; Labbate C; Jacob J; Murray K; Rose K; Sexton W; Dickstein R; Linehan J; Nieder A; Bjurlin M; Humphreys M; Ghodoussipour S; Quek M; O'Donnell M; Eisner BH; Matin SF; Lotan Y; Feldman AS
Urol Oncol; 2023 Sep; 41(9):387.e1-387.e7. PubMed ID: 37246135
[TBL] [Abstract][Full Text] [Related]
8. Oncologic and Safety Outcomes for Retrograde and Antegrade Endoscopic Surgeries for Upper Tract Urothelial Carcinoma: A Systematic Review and Meta-analysis.
Laukhtina E; Kawada T; Quhal F; Yanagisawa T; Rajwa P; von Deimling M; Pallauf M; Bianchi A; Majdoub M; Enikeev D; Fajkovic H; Teoh JY; Rouprêt M; Gontero P; Shariat SF
Eur Urol Focus; 2023 Mar; 9(2):258-263. PubMed ID: 36428210
[TBL] [Abstract][Full Text] [Related]
9. Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial.
Kleinmann N; Matin SF; Pierorazio PM; Gore JL; Shabsigh A; Hu B; Chamie K; Godoy G; Hubosky S; Rivera M; O'Donnell M; Quek M; Raman JD; Knoedler JJ; Scherr D; Stern J; Weight C; Weizer A; Woods M; Kaimakliotis H; Smith AB; Linehan J; Coleman J; Humphreys MR; Pak R; Lifshitz D; Verni M; Adibi M; Amin MB; Seltzer E; Klein I; Konorty M; Strauss-Ayali D; Hakim G; Schoenberg M; Lerner SP
Lancet Oncol; 2020 Jun; 21(6):776-785. PubMed ID: 32631491
[TBL] [Abstract][Full Text] [Related]
10. Antegrade administration of mitomycin gel for upper tract urothelial carcinoma via percutaneous nephrostomy tube: a multi-institutional retrospective cohort study.
Rose KM; Narang G; Rosen G; Labatte C; Dumitrascu CI; Campagna J; Yu A; Manley BJ; Spiess PE; Li R; Adibi M; Murray KS; Sexton WJ; Humphreys MR
BJU Int; 2023 Apr; 131(4):471-476. PubMed ID: 36285629
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of UGN-101, a mitomycin-containing reverse thermal gel instilled via retrograde catheter for the treatment of low-grade upper tract urothelial carcinoma.
Shabsigh A; Kleinmann N; Smith AB; Scherr D; Seltzer E; Schoenberg M; Lerner SP
Cancer Chemother Pharmacol; 2021 Jun; 87(6):799-805. PubMed ID: 33677615
[TBL] [Abstract][Full Text] [Related]
12. Durability of Response to Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101, a Mitomycin-Containing Reverse Thermal Gel: OLYMPUS Trial Final Report.
Matin SF; Pierorazio PM; Kleinmann N; Gore JL; Shabsigh A; Hu B; Chamie K; Godoy G; Hubosky SG; Rivera M; O'Donnell M; Quek M; Raman JD; Knoedler JJ; Scherr D; Weight C; Weizer A; Woods M; Kaimakliotis H; Smith AB; Linehan J; Coleman J; Humphreys MR; Pak R; Lifshitz D; Verni M; Klein I; Konorty M; Strauss-Ayali D; Hakim G; Seltzer E; Schoenberg M; Lerner SP
J Urol; 2022 Apr; 207(4):779-788. PubMed ID: 34915741
[TBL] [Abstract][Full Text] [Related]
13. Long-term endoscopic management of upper tract urothelial carcinoma: 20-year single-centre experience.
Cutress ML; Stewart GD; Wells-Cole S; Phipps S; Thomas BG; Tolley DA
BJU Int; 2012 Dec; 110(11):1608-17. PubMed ID: 22564677
[TBL] [Abstract][Full Text] [Related]
14. Long-term experience with bacillus Calmette-Guerin therapy of upper urinary tract transitional cell carcinoma in patients not eligible for surgery.
Thalmann GN; Markwalder R; Walter B; Studer UE
J Urol; 2002 Oct; 168(4 Pt 1):1381-5. PubMed ID: 12352398
[TBL] [Abstract][Full Text] [Related]
15. Clinical utility and concordance of upper urinary tract cytology and biopsy in predicting clinicopathological features of upper urinary tract urothelial carcinoma.
Simon CT; Skala SL; Weizer AZ; Ambani SN; Chinnaiyan AM; Palapattu G; Hafez K; Magers MJ; Kaffenberger SD; Spratt DE; Montgomery JS; Morgan TM; Udager AM; Lew M; Mehra R
Hum Pathol; 2019 Apr; 86():76-84. PubMed ID: 30537495
[TBL] [Abstract][Full Text] [Related]
16. Advances in chemoablation in upper tract urothelial carcinoma: overview of indications and treatment patterns.
Gottlieb J; Linehan J; Murray KS
Transl Androl Urol; 2023 Sep; 12(9):1449-1455. PubMed ID: 37814691
[TBL] [Abstract][Full Text] [Related]
17. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update.
Rouprêt M; Babjuk M; Compérat E; Zigeuner R; Sylvester RJ; Burger M; Cowan NC; Böhle A; Van Rhijn BW; Kaasinen E; Palou J; Shariat SF
Eur Urol; 2015 Nov; 68(5):868-79. PubMed ID: 26188393
[TBL] [Abstract][Full Text] [Related]
18. Induction and Maintenance Adjuvant Mitomycin C Topical Therapy for Upper Tract Urothelial Carcinoma: Tolerability and Intermediate Term Outcomes.
Metcalfe M; Wagenheim G; Xiao L; Papadopoulos J; Navai N; Davis JW; Karam JA; Kamat AM; Wood CG; Dinney CP; Matin SF
J Endourol; 2017 Sep; 31(9):946-953. PubMed ID: 28731777
[TBL] [Abstract][Full Text] [Related]
19. Impact of upper tract urothelial carcinoma on response to BCG in patients with non-muscle-invasive bladder cancer.
Bree KK; Hensley PJ; Brooks NA; Matulay J; Li R; Nogueras Gonzalez GM; Navai N; Grossman HB; Matin SF; Dinney CPN; Kamat AM
BJU Int; 2021 Nov; 128(5):568-574. PubMed ID: 33484074
[TBL] [Abstract][Full Text] [Related]
20. An evaluation of UGN-101, a sustained-release hydrogel polymer-based formulation containing mitomycin-C, for the treatment of upper urothelial carcinomas.
Porta C; Giannatempo P; Rizzo M; Lucarelli G; Ditonno P; Battaglia M
Expert Opin Pharmacother; 2020 Dec; 21(18):2199-2204. PubMed ID: 32870051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
